Prana Enrolls First Patient in the “Reach2HD” Phase II Huntington Disease Trial July 17, 2013August 16, 2022
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy September 20, 2022May 23, 2023
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy July 6, 2022May 23, 2023
